HomeFilePharmacology

Pharmacology

View Category

Antiplatelet

Xience Receives CE Mark for Short and Ultrashort DAPT Schemes

Dual antiplatelet therapy (DAPT) one month after angioplasty with Xience stent was approved in Europe for patients...
solaci -
Learn More
Antiplatelet

Dual Antiplatelet Therapy and TAVR: Obsolete Guidelines

The current guidelines recommend dual antiplatelet therapy (DAPT) 3 to 6 months after transcatheter aortic valve replacement...
solaci -
Learn More
Antithrombotic Anticoagulants

The Best Anticoagulant Agent for AF After TAVR

Direct anticoagulant agents were associated with lower long-term mortality in patients with atrial fibrillation (AF) discharged after...
solaci -
Learn More
Acute coronary syndromes

Post MI Betablockers for Good?

Patients receiving optimal medical treatment after MI do not seem to benefit from betablockers in the long...
solaci -
Learn More
Antiplatelet

Short Therapy and Monotherapy, Plenty of Evidence

A short dual antiplatelet therapy (DAPT) of 1 to 3 months followed by P2Y12 inhibitor monotherapy after...
solaci -
Learn More
Other

Diastolic Pressure Could Play a Dirty Trick on Patients Treated for Hypertension

Having too low diastolic pressure could be linked to an increase in cardiovascular events (J-shape phenomenon). However,...
solaci -
Learn More
Antithrombotic Anticoagulants

Major Cause of Myocardial Injury by COVID-19

The most common cause of myocardial necrosis in patient undergoing COVID-19 infection is microthrombi. These microthrombi resulted...
solaci -
Learn More
Antithrombotic Anticoagulants

AAS vs Warfarin in Low Risk TAVR

We are still discussing the adequate antithrombotic scheme after transcatheter aortic valve replacement (TAVR). Additionally, we are...
solaci -
Learn More